| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
1 Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas; 2 Department of Molecular Pharmacology, Stanford University School of Medicine, Stanford, California; and 3 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
The Akt kinase is a serine/threonine protein kinase that has been implicated in mediating a variety of biological responses. Studies show that high Akt activity in breast carcinoma is associated with a poor pathophenotype, as well as hormone and chemotherapy resistance. Additionally, high Akt activity is associated with other features of poor prognosis. Thus, a chemotherapeutic agent directed specifically toward tumors with high Akt activity could prove extremely potent in treating those breast tumors with the most aggressive phenotypes. Several studies have demonstrated that rapamycin, which inhibits mammalian target of rapamycin (mTOR), a downstream target of Akt, sensitizes certain resistant cancer cells to chemotherapeutic agents. This study evaluated the efficacy of mTOR inhibition in the treatment of tamoxifen-resistant breast carcinoma characterized by high Akt activity. We found that MCF-7 breast cancer cell lines expressing a constitutively active Akt are able to proliferate under reduced estrogen conditions and are resistant to the growth inhibitory effects of tamoxifen, both in vitro as well as in vivo in xenograft models. Cotreatment with the mTOR inhibitor rapamycin in vitro, or the ester of rapamycin, CCI-779 (Wyeth) in vivo, inhibited mTOR activity and restored sensitivity to tamoxifen, suggesting that Akt-induced tamoxifen resistance is mediated in part by signaling through the mTOR pathway. Although the mechanism underlying the synergism remains to be understood, the results were associated with rapamycin’s ability to block transcriptional activity mediated by estrogen receptor 
, as assessed by reporter gene assays with estrogen-responsive element luciferase. These data corroborate prior findings indicating that Akt activation induces resistance to tamoxifen in breast cancer cells. Importantly, these data indicate a novel mechanism for tamoxifen resistance and suggest that blockage of the phosphatidylinositol 3'-kinase/Akt signaling pathway by mTOR inhibition effectively restores the susceptibility of these cells to tamoxifen. These data may have implication for future clinical studies of mTOR inhibition in breast carcinoma.
This article has been cited by other articles:
|
|
 |
|
  T. S. Chu, J. S. Chen, J. P. Lopez, F. S. Pardo, J. Aguilera, and W. M. Ongkeko Imatinib-Mediated Inactivation of Akt Regulates ABCG2 Function in Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, September 1, 2008; 134(9): 979 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yu, G. Shen, T. O. Khor, J.-H. Kim, and A.-N. T. Kong Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism Mol. Cancer Ther., September 1, 2008; 7(9): 2609 - 2620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Arpino, L. Wiechmann, C. K. Osborne, and R. Schiff Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance Endocr. Rev., April 1, 2008; 29(2): 217 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Mita, A. C. Mita, Q. S. Chu, E. K. Rowinsky, G. J. Fetterly, M. Goldston, A. Patnaik, L. Mathews, A. D. Ricart, T. Mays, et al. Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies J. Clin. Oncol., January 20, 2008; 26(3): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yoon, M.-Y. Lee, S. W. Park, J.-S. Moon, Y.-K. Koh, Y.-H. Ahn, B.-W. Park, and K.-S. Kim Up-regulation of Acetyl-CoA Carboxylase {alpha} and Fatty Acid Synthase by Human Epidermal Growth Factor Receptor 2 at the Translational Level in Breast Cancer Cells J. Biol. Chem., September 7, 2007; 282(36): 26122 - 26131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Beeram, Q-T. Tan, R. Tekmal, D Russell, A Middleton, and L. deGraffenried Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling Ann. Onc., August 1, 2007; 18(8): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Massarweh and R. Schiff Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities Clin. Cancer Res., April 1, 2007; 13(7): 1950 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lehnes, A. D. Winder, C. Alfonso, N. Kasid, M. Simoneaux, H. Summe, E. Morgan, M. C. Iann, J. Duncan, M. Eagan, et al. The Effect of Estradiol on in Vivo Tumorigenesis Is Modulated by the Human Epidermal Growth Factor Receptor 2/Phosphatidylinositol 3-Kinase/Akt1 Pathway Endocrinology, March 1, 2007; 148(3): 1171 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rubio-Viqueira, H. Mezzadra, M. E. Nielsen, A. Jimeno, X. Zhang, C. Iacobuzio-Donahue, A. Maitra, M. Hidalgo, and S. Altiok Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays Mol. Cancer Ther., February 1, 2007; 6(2): 515 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zarogiannis, C. Hatzoglou, P. A. Molyvdas, and K. Gourgoulianis Lymphangioleiomyomatosis Eur. Respir. J., December 1, 2006; 28(6): 1284 - 1284. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yu and E. P. Henske Estrogen-Induced Activation of Mammalian Target of Rapamycin Is Mediated via Tuberin and the Small GTPase Ras Homologue Enriched in Brain Cancer Res., October 1, 2006; 66(19): 9461 - 9466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hidalgo, J. C. Buckner, C. Erlichman, M. S. Pollack, J. P. Boni, G. Dukart, B. Marshall, L. Speicher, L. Moore, and E. K. Rowinsky A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer. Clin. Cancer Res., October 1, 2006; 12(19): 5755 - 5763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T M Sadler, M Gavriil, T Annable, P Frost, L M Greenberger, and Y Zhang Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr. Relat. Cancer, September 1, 2006; 13(3): 863 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bon, V. Folgiero, G. Bossi, L. Felicioni, A. Marchetti, A. Sacchi, and R. Falcioni Loss of {beta}4 Integrin Subunit Reduces the Tumorigenicity of MCF7 Mammary Cells and Causes Apoptosis upon Hormone Deprivation. Clin. Cancer Res., June 1, 2006; 12(11): 3280 - 3287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R.D. Johnston Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 and Mammalian Target of Rapamycin in Breast Cancer Clin. Cancer Res., February 1, 2006; 12(3): 1061s - 1068s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lin, P. L. Zhang, X. J. Yang, J. W. Prichard, M. Lun, and R. E. Brown Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated mTOR Pathway in Renal Cell Carcinomas Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 283 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Basso, A. Mirza, G. Liu, B. J. Long, W. R. Bishop, and P. Kirschmeier The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling: ROLE IN FTI ENHANCEMENT OF TAXANE AND TAMOXIFEN ANTI-TUMOR ACTIVITY J. Biol. Chem., September 2, 2005; 280(35): 31101 - 31108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Boulay, J. Rudloff, J. Ye, S. Zumstein-Mecker, T. O'Reilly, D. B. Evans, S. Chen, and H. A. Lane Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5319 - 5328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S R D Johnston Clinical trials of intracellular signal transductions inhibitors for breast cancer -- a strategy to overcome endocrine resistance Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S145 - S157. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
